

PROFILES
AUGUST 27, 2015

DR. A. GEORGE (GIRGIS) AWAD

Articles in Refereed Journals

- **Awad, A.G.**, Voruganti L.N.P. Revisiting the self-medication hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behaviour. *Ther. Adv. Psychopharmacol* 2015, 5:172-178.
- **Awad, A.G.** et al. Health-related quality of life among patients treated with Lurasidone: results from a switch trial in patients with schizophrenia. *BMC Psychiatry* 2014, 14:53-62.
- **Awad, A.G.** The Patient - At the Centre of Evolving Psychiatric Care. *Bulletin of General Practitioner Psychotherapy Association* 2014, in press.
- **Awad, A.G.**, Voruganti, L.N.P. The Impact of Newer Atypical Antipsychotics on Patient-Reported Outcomes in Schizophrenia. *CNS Drugs* 2013, 27: 625-636.
- **Awad, A.G.** Is it time to Consider Comorbid Substance Abuse as a New Indication for Antipsychotic Drug Development? *J. Psychopharmacology* 2012, 26: 953-958.
- **Awad, A.G.**, Voruganti, L.N.P. Measuring Quality of Life in patients with Schizophrenia – An Update. *Pharmacoeconomics* 2012; 30 (3): 183-195.
- Saleem F., Hassali M.A., Shafia A., Atif, M., **Awad, A.G.** Predictors of Medication Adherence in a Hypertensive Population in Pakistan. *Latin Amer. Journal Pharmacy* 2011, 30: 1714-1719.
- **Awad A.G.** Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. (Editorial) *Expert Review, Pharmacoeconomics and Outcomes research* 2010, 10:1-4.
- Vernon M., Revicki D., **Awad A.G.**, Dirani R., Panish J, Canuso, C, Grinspan, Mannix S. Kalali A. Psychometric evaluation of medications satisfaction questionnaire (MSQ) to assess satisfaction with antipsychotic medications among schizophrenic patient. *Schizophrenia Research* 2010, 118: 271-278..
- Ascher-Svanum H., Nyhuis A.W., Stauffer V., Kiman J, Farries D.F., Philipps G., **Awad A.G.**, Keefe R., Naber D, Perkins, D. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia form the patient and clinician perspective. *Curr Med. Res. Opin.* 2010, 10: 2403-2410.
- Canuso C., Grinspan, Damaraju C.V., Meriman U, Alphas L, **Awad A.G.** Medication satisfaction in schizophrenia –a blind initiation study of paliperidone ER in patients sub optimally responsive to risperidone. *Int. Clin Psychopharmacology* 2010, 25: 155-164.
- Kemp A., Alphas, L, Anand R, **Awad A.G.**, Davidson M, Dube S, Ereshefsky, Gharabawi

G, Kalali A, Leon A., Lepine J.P., Potkin S., Schooler N., Vermeulen A., What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? *Schizophr Bulletin* 2008, 10.1093/schbul/sbn110.

- **Awad, A.G.**: Schizophrenia, Medications and the Issue of Quality of Life. *Journal of Uruguayan Psychiatric Association* 2008, 72: 121-129.

- **Awad, A.G.**, Voruganti, L.N.P.: Family burden of care in schizophrenia, a review. *Pharmacoeconomics* 2008, 26: 149-162.

- Voruganti, L.N.P., Baker, L., **Awad, A.G.**: New generation antipsychotic drugs and compliance behaviour. *Current Opinion in Psychiatry* 2008, 21: 1-7.

- Voruganti, L.N.P., **Awad, A.G.**: Cognition, functioning and quality of life in schizophrenia: results of one year randomised controlled trials of Olanzapine and Quetiapine. *Schizophrenia Research* 2007, 96: 146-155.

- Voruganti, L.N.P., Punthakee, Z., Van Lieshout, MacCrimmon, D., Parker, D., **Awad, A.G.**, Gerstein, H.C.: Dysglycemia in a community sample of people treated for schizophrenia: The diabetes in schizophrenia in Central-South Ontario (DiSCO) study. *Schizophrenia Research* 2007, 10.1016/J. Schres 2007.07.016.

- **Awad, A.G.**, Rajagoplan, K., Bolge, S., McDonnell, D.: "Quality of Life Among Bipolar Disorder patients Misdiagnosed with Major Depressive Disorder". *Prime Care Companion, J Clin Psychiatry* 2007, 9: 195-202

- Gharabawi G.M., Greenspan A., Rupnow C.H.,F., Kosik-Gonzalez, Bossie C.A., Zhu X., Kalali A., **Awad A.G.** Reduction in psychotic symptoms as a predictor of patients satisfaction with antipsychotic medications in schizophrenia data from a randomized double-blind trial. *BMC Psychiatry* 2006, 6:45.

- Voruganti, L.N.P., **Awad, A.G.**: Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia – findings from an inVIVO SPECT study. *Schizophrenia Research* 2006, doi: 10.1016/J. Schres, 2006.07-012.

- **Awad, A.G.**, Greenspan, A., Kosik-Gonzales, C et al: Prediction of patient satisfaction with medications in patients with schizophrenia. *Neuropsychopharmacology* 2005, 30: 115-116.

- **Awad, A.G.**, Naber, D.: "Neuroleptic Dysphoria 50 Years Later". *Acta Psychiatr Scand Suppl.* 2005, (427):5. (Editorial)

- **Awad, A.G.**, Voruganti, L.N.P.: Research into primary prevention of diabetes in schizophrenia: Methodological consideration. *Schizophrenia Bulletin.* 2005, 31: 337-338.

- **Awad, A.G.**, Voruganti L.N.P.: "Neuroleptic Dysphoria: Revisiting the Concept 50

- Years Later". *Acta Psychiatr Scand Suppl.* 2005, (427):6-13.
- Adams, C.E., Rathbone, J., Thornley, B., Clarke, M., Borrill, J., Wahlbeck, K., **Awad, A.G.**: "Chlorpromazine for Schizophrenia: A Cochrane Systematic Review of 50 Years of Randomised Controlled Trials". *BMC Med.* 2005, Oct 17;31):15.
 - Voruganti L.N.P., **Awad, A.G.**: "Brain Imaging Research on Subjective Responses to Psychotropic Drugs". *Acta Psychiatr Scand Suppl.* 2005, (427): 22-28.
 - **Awad, A.G.**: "Second Generation Antipsychotics – Beyond Efficacy". (Editorial), *Canadian Journal of Psychiatry* 2004, 49:283-284.
 - **Awad, A.G.**, Voruganti L.N.P., Neuroleptic dysphoria from conventional to new antipsychotics – data from long-term switch studies. *Journal of Neuropsychopharmacology* 2004, 7: 38-39.
 - **Awad, A.G.**, Voruganti L.N.P.: "Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia". *CNS Drugs* 2004, 18:877-893.
 - **Awad A.G.**, Voruganti L.N.P.: "Body Weight, Image and Self-esteem Evaluation (B-WISE) Questionnaire: Development and Validation of a new Scale" *Schizophrenia Research* 2004, 70:63-67.
 - **Awad, A.G.** "Antipsychotic Medications: Compliance & Attitudes Towards Treatment. *Current Opinion in Psychiatry* 2004, 17:75-80.
 - **Awad, A.G.**, Voruganti L.N.P.: "New Antipsychotics, Compliance, Quality of Life and Subjective Tolerability – Are Patients Better Off? *Canadian Journal of Psychiatry* 2004, 49:297-302.
 - Voruganti L.N.P., **Awad, A.G.**: "Neuroleptic Dysphoria as a Variant of Extrapramidal Symptoms". *Canadian Journal of Psychiatry* 2004, 49:285-289.
 - Voruganti L.N.P., **Awad, A.G.**: "Neuroleptic Dysphoria: Towards a New Synthesis" *Psychopharmacology*, 171: 121-132, 2004.
 - **Awad, A.G.**, Voruganti L.N.P., Mackell J., Siu, C.O.: Subjective tolerability with Ziprasidone vs. Haloperidol in acute schizophrenia. *Value in Health*, 2003, 6.
 - **Awad, A.G.**, Voruganti, L.N.P.: The Subjective/objective dichotomy in schizophrenia – from dysphoria to striatal dopamine receptors. *Schizophrenia Bulletin* 2002, 53, 199-200.
 - Voruganti L.N.P., Cortese L., Oweyemi, Kottedda V., Cernovsky A., Sirul S., **Awad A.G.**: "Switching from Conventional to Novel Antipsychotic Drugs: Results of a Prospective, Naturalistic Study". *Schizophrenia Research* 57: 201-208, 2002.

- Voruganti L.N.P., **Awad A.G.** Personal Evaluation of Transition in Treatment (PETiT) Development and Testing in Schizophrenia. *Schizophrenia Research*, 56: 37-46, 2002.
- Dott, S.G., Weiden, P., Hopwood, P., **Awad, A.G.**, Hellewell, J.S., Knesevich, J., Kopala, L., Miller, A., Haimov, C.S.: "An Innovative Approach to Clinical Communication in Schizophrenia: the Approaches to Schizophrenia Communication Checklists". *CNS Spectr.* 2001, Apr; 6 (4):333-8.
- Voruganti L.N.P., Slomka P., Zabel P., Costa G., So A., Mattar A., **Awad A.G.**: "Subjective Effects of AMPT-induced Dopamine Depletion in Schizophrenia". Correlation between Dysphoric responses and Striatal D2 binding ratios on SPECT imaging. *Neuropsychopharmacology* 25: 641-650, 2001.
- Voruganti, L.N.P., Slomka P., Zabel P., Mallar A., **Awad A.G.** "Cannabis-induced Dopamine Release: an in-vivo SPECT Study; *Psychiatry Research, Neuroimaging* 107: 173-177, 2001.
- **Awad A.G.**, Voruganti L.N.P. "Intervention Research in Psychosis - Issues Related to the Assessment of Quality of Life". *Schizophrenia Bulletin* 26: 557-564, 2000.
- Voruganti L.N.P., **Awad A.G.** et al. "Cost Utility Analysis in Schizophrenia - A Feasibility Study. *PharmacoEconomics* 17: 273-286, 2000.
- Voruganti L.N.P., Cortese L., Oyewmi L., Cernovsky Z, Zirul, S., **Awad A.G.** "Quality of Life and Subjective Tolerability of Conventional and New Antipsychotics in Schizophrenia" - A Comparative study. *Schizophrenia Research* 43: 135-145, 2000.
- Ramasubba R., Flint, A., Brown, G., **Awad, A.G.**, Kennedy S.: Neurohormonal responses to D-fenfluramine in healthy elderly subjects. A placebo-controlled study. *Psychoneuroendocrinology* 2000, 25: 139-150.
- **Awad A.G.**, Voruganti L.N.P. "Quality of Life and New Antipsychotic Medications - Are Patients Better Off?" *Int. Journal of Social Psychiatry*: 45 (4) 311-319, 1999.
- Hellewell J., Kalali A.H., Langham S.J., McKellar J., **Awad A.G.** "Patient Satisfaction and Acceptability of Long-term Treatment with Quetiapine". *International Journal of Psychiatry in Clinical Practice*. 3: 105-113, 1999.
- Lapierre Y.D., Angus C., **Awad A.G.**, et al.: "The Treatment of Negative Symptoms: A Clinical and Methodological Study". *International Clinical Psychopharmacology*. 14: 101-112, 1999.
- **Awad A.G.**, Voruganti L.N.P.: "Cost Utility Analysis in Schizophrenia". *Journal of Clinical Psychiatry*; Vol. 60, Suppl. 3, pgs. 22-29, 1999.
- Voruganti L.N.P., Heslegrave R. J., **Awad A.G.**, Seeman, M. "Quality of Life

Measurement in Schizophrenia: Reconciling the Question of Subjectivity with the Quest for Reliability. *Psychological Medicine* 28: 165-172, 1998.

- Thornley, B, Adams, C, **Awad A.G.**: Chlorpromazine versus placebo for the treatment of schizophrenia a systematic review. *Schiz. Research* 1998, 29: 199- 200.
- Thornley B., Adams C.E., **Awad A.G.** Chlorpromazine versus Placebo for Schizophrenia - 50 Years Later *BMJ*. 317: 1181-1184, 1998.
- Ramasubba R., Flint A., Brown G., **Awad A.G.**, Kennedy S.: "A Neuroendocrine Study of Serotonin Function in Depressed Stroke Patients and Healthy Controls". *J. Aff Dis*, 1999, 52: 121-133.
- Ramasubba R., Kennedy S., Flint A., Brown G., **Awad A.G.**, Cooper T., "Diminished Serotonin Mediated Prolactin Responses in Nondepressed Stroke Patients Compared to Healthy Normals". *Stroke* 1998; 29:1293-1298.
- **Awad A.G.**, Voruganti L.N.P., Heslegrave R.J. "A Conceptual Model of Quality of Life in Schizophrenia": Description and Preliminary Clinical Validation. *Quality of Life Research*, 6:21-26, 1997.
- **Awad A.G.**, Voruganti L.N.P., Heslegrave R. J. "Measurement of Quality of Life in Schizophrenia." *Pharmacoeconomics* 11:32-47, 1997.
- Wong A, Voruganti L.N.P., Heslegrave R. J., **Awad A.G.** "Neurocognitive Deficits and Neurological Signs in Schizophrenia." *Schizophrenia Research*. 23: 139-146, 1997.
- **Awad A.G.**, Lapierre Y., Angus C., Rylander A., et al. "Quality of Life and Response of Negative Symptoms in Schizophrenia to Haloperidol and the Atypical Remoxipride." *Journal of Psychiatry and Neuroscience* 22: 244-248, 1997.
- **Awad A.G.** "Quality of Life Rediscovered - (Editorial) *Journal of Psychiatry and Neuroscience* 22: 229-230, 1997.
- Voruganti L.N.P., Heslegrave R. J., **Awad A.G.** "Neuroleptic Dysphoria May Be The Missing Link Between Schizophrenia and Substance Abuse." *Journal of Nervous and Mental Diseases* 185: 463-465, 1997.
- Voruganti L.N.P., Heslegrave R. J., **Awad A.G.** "Quality of Life Measurement during Antipsychotic Therapy in Schizophrenia." *Journal of Psychiatry and Neuroscience*, 22: 267-274, 1997.
- Heslegrave R. J., **Awad A.G.**, Voruganti L.N.P. "The Influence of Neurocognitive Deficits and Symptoms on Quality of Life in Schizophrenics." *Journal of Psychiatry and Neuroscience*, 22: 235-243, 1997.

- Voruganti L.N.P., Heslegrave R. J., **Awad A.G.** “Neurocognitive Correlates of Positive and Negative Symptoms in Schizophrenia.” *Canadian Journal of Psychiatry* 42: 1066-1071, 1997.
- Heslegrave R. J., **Awad A.G.**, Voruganti L.N.P., “Assessing Quality of Life in Persons with Chronic Mental Illness and Neurocognitive Deficits.” *Journal on Developmental Disabilities* 5: 77-90, 1997.
- **Awad A.G.**, Voruganti L.N.P., Heslegrave R.J., Hogan T.P. “Assessment of Subjective Response to Neuroleptics in the Acute Phase of Schizophrenia - Implications for Compliance and Outcome.” *International Clinical Psychopharmacology*. 11 (Suppl. 2) 55-60, 1996.
- **Awad A.G.**, Voruganti L.N.P., Heslegrave, R.J. “The Aims of Antipsychotic Medication - What are They and are They being Achieved?” *CNS Drugs* 4:8-16, 1995.
- **Awad A.G.**, Hogan T.P., Voruganti L.N.P., Heslegrave R.J. “Patients’ Subjective Experiences on Antipsychotic Medications - Implications for Outcome and Quality of Life.” *International Clinical Psychopharmacology* 10:123-132, 1995.
- **Awad A.G.**, Hogan T.P.: **Subjective** Response to Neuroleptic and Quality of Life - Implications for Treatment Outcome.” *Acta Psychiatrica Scandinavia*, 89 (Suppl. 380):27-32, 1994.
- Adams C., Anderson J., **Awad A.G.**, et al., “Schizophrenia and the Cochrane Collaboration. *Schizophrenia Research* 13: 185-188, 1994.
- **Awad A.G.**, “Design and Methodological Issues in Clinical Trials of New Neuroleptics.” *British Journal of Psychiatry*, 163 (Suppl. 22), 51-57, 1993.
- **Awad A.G.**, “Quality of Life of Schizophrenics on Medications - Implications for Clinical Trials of New Neuroleptics.” *Hospital and Community Psychiatry*, 32: 262-265, 1992.
- **Awad A.G.**, “Neuroleptic Dysphoria and its Relevance to Clinical Management in Schizophrenia.” *Schizophrenia Research*, 9: 49-51, 1992.
- Collins E., Hogan T.P., **Awad A.G.**, “The Pharmacoepidemiology of Treatment Refractory Schizophrenia.” *Canadian Journal of Psychiatry*, 37, 4: 192-195, 1992.
- Hogan T.P., **Awad A.G.**, “Subjective Response to Neuroleptic and Outcome in Schizophrenia: A Re-examination Comparing Two Measures.” *Psychological Medicine*, 22: 347-352, 1992.
- **Awad A.G.**, “Neuroleptic Dysphoria and Clinical Management in Schizophrenia.” *Contemporary Psychiatry*, 10: 9-14, 1992.

- Heinrichs R.W., **Awad A.G.**, "Neurocognitive Subtypes of Chronic Schizophrenia." *Schizophrenia Research*, 9: 49-58, 1992.
- Lapierre Y., Ancill R., **Awad A.G.** et al. "A Dose-Finding Study with Remoxipride in the Acute Treatment of Schizophrenic Patients." *Journal of Psychiatry and Neuroscience*, 17: 134-154, 1992.
- **Awad A.G.**, Darby P., Garfinkel P. "Psychopharmacology Training in Psychiatric Residency Programs - The Canadian Scene." *Canadian Journal of Psychiatry*, 36: 21-15, 1991.
- **Awad A.G.**, Lapierre Y.D., Jostell K.G., et al. "Selective Dopamine D2 Antagonist and Prolactin Response in Schizophrenia - Results of Remoxipride Studies." *Progress in Neuropsychopharmacology & Biol. psychiat.* 14: 767-777, 1990.
- Jostell K.G., Lapierre Y.D., Ancill R.J., **Awad A.G.** et al, and the Canadian Remoxipride Study Group. "Plasma concentration of Remoxipride in Relation to Antipsychotic Effect and Adverse Symptoms." *Acta. Psychiatr. Scand.* 82, 48-50, 1990.
- Lapierre Y.D., Nair N.V.P., Chouinard G., **Awad A.G.**, et al. "A Controlled Dose-Ranging Study of Remoxipride v.s. Haloperidol in Schizophrenia in a Canadian Multicentre Trial." *Acta. Psychiatric Scand.* 82, 72-76, 1990.
- **Awad A.G.** "Drug Therapy in Schizophrenia - Variability of Outcome and Prediction of Response." *Can. J. Psych.* 34, 711-720, 1989.
- **Awad A.G.** "Depression, Antidepressants and Receptors." *Contemporary Psychiatry*, 7, 175-177, 1988.
- **Awad A.G.**, "Drug Response in Schizophrenia - Prediction of Outcome." *Schizophrenia Res.*, 1: 221-222, 1988.
- **Awad A.G.**, Hogan T.P. "Diagnostic Criteria and Drug Response in Schizophrenia." *Med. Sci. Res.*, 16, 199-200, 1988.
- **Awad A.G.**, "Integrating a Clinical Review Program with Post-Graduate Training in Clinical Psychopharmacology." *Quality Review Bulletin*, 13, 279-282, 1987.
- **Awad A.G.**, Hogan T.P. "Toward the Development of a Strategy for Individualized Drug Therapy in Schizophrenia." *Am. J. Hospital Formulary*, 22, 480-486, 1987.
- **Awad A.G.**, "New Antidepressants - The Serotonin Re-uptake Inhibitors." *Psychiatric Journal, University of Ottawa*, 12, 31-34, 1987.
- **Awad A.G.**, "Measurement of Quality of Care in Mental Health Services; Is It Possible?"

Quality Assurance Quarterly, 2, 12-16, 1986.

- **Awad A.G.**, Hogan T.P., "Early Treatment Events and Prediction of Response to Neuroleptics." *Progress in Neuropsychopharmacology and Biological Psychiatry*, Vol. 9, 585-588, 1985.
- **Awad A.G.**, "Do We Need New Antidepressants?" *Annals of the Royal College of Physicians and Surgeons*, 18, 333-338, 1985.
- Hogan T.P., **Awad A.G.**, Eastwood M.R., "Early Treatment Events and Variability in Outcome to Neuroleptics." *Can. J. Psych.* 30, 246-248, 1985.
- **Awad A.G.**, "Prediction of Response to Neuroleptic Drug Therapy in Schizophrenia." *Can. J. Psych.* 20, 241-243, 1985.
- **Awad A.G.**, Kugelmass M., "Fluspirilene a Long-Acting Antipsychotic in the Treatment of Acute Decompensation in Schizophrenia." *Current Ther. Res.* 36, 456-460, 1984.
- **Awad A.G.**, "Diet and Drug Interactions in the Treatment of Mental Illness." *Can. J. Psych.* 29, 609-613, 1984.
- Lang A.E., Moldofsky H., **Awad A.G.**, "Long Latency Between the Onset of Motor and Vocal Tics - Tourettes Syndrome." *Ann. Neurology*, 1, 693-394, 1983.
- **Awad A.G.**, "Schizophrenia and Multiple Sclerosis." *J. Nerv. Ment. Dis.*, 171, 223-224, 1983.
- **Awad A.G.**, "Development of a New Model for Post-Graduate Training in the Proper Use of Psychoactive Drugs." *Annals of the Royal College of Physicians and Surgeons of Canada* 16, 229-232, 1983.
- Hogan T.P., **Awad A.G.**, "Pharmacotherapy and Suicide Risk in Schizophrenia." *Can. J. Psych.*, 28, 277-281, 1983.
- Hogan T.P., **Awad A.G.**, Eastwood M.R., "A Self-Report Scale Predictive of Drug Compliance in Schizophrenics: Reliability and Discriminative Validity." *Psychological Md.*, 13, 177-183, 1983.
- Uldall P.R., **Awad A.G.**, McCormick W.O., et al. "A Study of Renal Function in Patients on Long-Term Lithium Therapy." *CMAJ*, 124, 1471-1474, 1981.
- **Awad A.G.**, Durost B., Gray J., Kugelmass M., Smith C. "Psychiatric Audits - The Ontario Scene." *Can. J. Psych.* 25, 155-162, 1980.
- Sen A.K., Stancer H.C., **Awad A.G.** "Urinary c-AMP in Manic Depressive Disease." *J. Ment. Nerv. Dis.*, 163, 210-213, 1976.

- Sellers E.M., **Awad A.G.**, Schonbaum E., “Long-Acting Thyroid Stimulator in Graves’ Disease. *Lancet*, 335-338, 1970.
- **Awad A.G.**, Carloni C., Carpi A., “Effects of Aldosterone, Dexamethasone and Corticosterone on the Cardiovascular Reactivity of Adrenolectromized rats.” *Arch. Internat. Pharmac. Therapy*, 98-111, 1969.
- **Awad A.G.**, Shedrina R.N., “On the Blocking Effects of DOCA on ACTH Secretion - Relative to Experimental Stress.” *Prob. Endocrinal*. 2, 67-72, 1965.

• Editorials

- The Editor in Chief: The Canadian Psychiatric Association: The Bulletin (1998-2003). Contributed editorials, as well as a regular column (Psychopharmacology Update) six times a year, which bridge the gap between research and clinic practice.
- **Awad A.G.** - Light Treatment for Non-seasonal Depressions and Intermittent Neuroleptic Treatment and Risk for Tardive Dyskinesia: *Bulletin* 30, N4, August 1998.
- **Awad A.G.** - Haloperidol Plasma Levels and Dose Optimization and Mood Stabilizer Combinations: *Bulletin* 30, N2, April 1998.
- **Awad A.G.** - Adjunctive Fluoxetine Treatment in Anorexia and Divalproex as Alternative Treatment for Demented Elderly Aggressive Patients: *Bulletin* 30, N1, February 1998.
- **Awad A.G.** - Time to Clozapine Response and Fluoxetine Augmentation of Clozapine Treatment: *Bulletin* 29, N6, December 1997.
- **Awad A.G.** - Venlafaxine in the Treatment of Children and Adolescents with Depression and Neuroleptic Dysphoria as the Missing Link between Schizophrenia and Substance Abuse: *Bulletin* 29, N5, October 1997.
- **Awad A.G.** - Pharmacological treatment of somatization/hypochondriasis. Buspirone in social phobia, *Bulletin* 29, N4, August 1997.
- **Awad A.G.** - Effect of Pindolol in Hastening Response to Fluoxetine. Amantadine in the Treatment of Tardive Dyskinesia (*Bulletin* 29, N3, June 1997).
- **Awad A.G.** - Adjunctive Medications in the Treatment of Depressed Elderly. Long-term Pharmacotherapy in Obsessive Compulsive Disorder. (*Bulletin*, Vol. 29, N2 April 1997).
- **Awad A.G.** - Safety of Combined S.S.R.I.’s and Moclobemide. (*Bulletin*, Vol. 29, N1

February 1997).

- **Awad A.G.** - Anticholinergic Prophylaxis During Neuroleptic Therapy Revisited. Antidepressant Therapy During Breast-Feeding. (Bulletin, Vol. 28, N6 December 1996).
- **Awad A.G.** - Urinary Incontinence and Clozapine Treatment in Schizophrenia.-Clozapine and Water Intoxication in Schizophrenia. (Bulletin, Vol. 28 N5 October 1996).
- **Awad A.G.** - S.S.R.I. and Premature Ejaculation. Prediction of Response to Mood Stabilizers. (Bulletin, Vol. 28, N4 August 1996).
- **Awad A.G.** - Drug Interactions: Lithium and Angio-Tension Converting Enzyme Medications for Treatment of Hypertension - Cisapride for the Treatment of SSRI Induced Nausea (Bulletin, Vol. 28, N3 June 1996)
- **Awad A.G.** - Postpartum Prophylaxis for Women with Bipolar Illness. Clozapine-induced Neuroleptic Malignant Syndrome. (Bulletin, Vol. 28, N2 April 1996).
- **Awad A.G.** - Lithium in the Treatment of Aggressive Children and Adolescents with Conduct Disorder. (Bulletin, Vol. 27, N6 December 1995).
- **Awad A.G.** Clozapine-induced Hallucinations and Complex Partial Seizures. Switch from Tricyclics to Moclobemide. (Bulletin, Vol. 27, N5 October 1995).
- **Awad A.G.** - Gender Differences in Onset, Course and Treatment Response in First Episode Schizophrenia S.S.R.I.'s and P.M.S. (Bulletin, Vol. 27, N4 August 1995).
- **Awad A.G.** - S.S.R.I.'s and Alcohol Dependence. (Bulletin, Vol. 27, N3 June 1995).
- **Awad A.G.** - Maintenance Antidepressants in Secondary Depression in Schizophrenia. Serotonin and Aggressive Personality. (Bulletin, Vol. 27, N2 April 1995).

• **Book Chapters**

- **Awad A.G.** "Quality of Life Measurements in a Person with Schizophrenia." Handbook of Psychiatric Measurements in Schizophrenia. Springer Verlag 2012.
- **Awad A.G.**, Voruganti L.N.P.: "New Antipsychotics and the Issue of Quality of Life in: Ritsner, M., **Awad A.G.** (eds) Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders: New Perspectives on Treatment and Research"; Springer 2007, pp. 307-320.

- Voruganti, L.N.P., **Awad, A.G.**: “Role of Dopamine in Pleasure, Reward and Subjective Responses to Drugs: in Ritsner, M., **Awad A.G.** (eds) Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorder. Springer 2007, pp. 21-32.
- **Awad A.G.**: “The Psychology of Medication-taking. The Development of a Research Program in Psychopharmacology. A Personal Account” in: (eds) Ban T.A., Healy D., Shorter E.: From Psychopharmacology to Neuro-psychopharmacology in 1980s. CINP, 2002, pp 130-134.
- **Awad A.G.**, Voruganti L.N.P.: “The Subjective/Objective Dichotomy: Implications for Nosology, Treatment and Research (editor: W. Gaebel). Zukunftsperspektiven in Psychiatrie und Psychotherapie. Steinkopff, Darmstadt, Germany 2002, pp 21-27.
- Barnes T., **Awad A.G.**, “Strategies to Enhance Medication Compliance” In: Schizophrenia and Mood Disorders: New Drug Therapies in Clinical Practice. (Eds.) Buckley P., Waddington J.; Butterworth-Heinemann 2000, pp. 317 - 329.
- **Awad A.G.**, Voruganti L.N.P., Heslegrave R.J.: “Measuring Quality of Life in Patients with Schizophrenia”. In (ed.) G. Mallarkey: Managing Schizophrenia - Adis International; pgs. 59-75, 1999.
- **Awad A.G.**: “Behavioural and Subjective Effects of Atipsychotic Medications”. In J. Kane (ed); Managing the Side-Effects of Drug Therapy in Schizophrenia. SP Science Press 2001, pp 1 -14.
- **Awad A.G.**, “Antipsychotic Medications - How Satisfied Are Our Patients”. In: Patient Satisfaction, Compliance and Outcomes in Schizophrenia. (Eds.) Hellewell J., Awad A.G., Clear Perspectives Series; Shire Hall Publications, London, U.K, 1999.
- **Awad A.G.**, Voruganti L.N.P, “Neuroleptics and Quality of Life in Schizophrenia” In: Quality of Life and Mental Health Care. (Eds.) Priebe S., Oliver J., Kaiser W. Wrightson Biomedical Publishing, London U.K. Pgs 119-125, 1999.
- Lozon J., Rowand S., **Awad A.G.**, de Waal L., Moffat M., “Strategic Alliances in Health Care.” The Wellesley/St. Michael’s Mental Health Program in: Strategic Alliances in Health Care. Eds: P. Leatt et al, Canadian College of Health Services Executives 1996, pps. 31-40.
- **Awad A.G.**, “Psychopharmacology Research in Canada.” In Images in Psychiatry: Ed: Rae-Grant Q. World Psychiatric Association Publication - American Psychiatric Press, Washington.
- **Awad A.G.**, “Quality of Life Issues in Medicated Schizophrenics.” In Contemporary Issue in the Treatment of Schizophrenia. Eds. C.L. Shriqui and H. Nasrallah. American Psychiatric Press, 1995.

- Voruganti, L.N.P., **Awad, A.G.**: “Role of Dopamine in Pleasure, Reward and Subjective Responses to Drugs: in Ritsner, M., **Awad A.G.** (eds) Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorder. Springer 2007, pp. 21-32.
- **Awad A.G.**: “The Psychology of Medication-taking. The Development of a Research Program in Psychopharmacology. A Personal Account” in: (eds) Ban T.A., Healy D., Shorter E.: From Psychopharmacology to Neuro-psychopharmacology in 1980s. CINP, 2002, pp 130-134.
- **Awad A.G.**, Voruganti L.N.P.: “The Subjective/Objective Dichotomy: Implications for Nosology, Treatment and Research (editor: W. Gaebel). Zukunftsperspektiven in Psychiatrie und Psychotherapie. Steinkopff, Darmstadt, Germany 2002, pp 21-27.
- Barnes T., **Awad A.G.**, “Strategies to Enhance Medication Compliance” In: Schizophrenia and Mood Disorders: New Drug Therapies in Clinical Practice. (Eds.) Buckley P., Waddington J.; Butterworth-Heinemann 2000, pp. 317 - 329.
- **Awad A.G.**, Voruganti L.N.P., Heslegrave R.J.: “Measuring Quality of Life in Patients with Schizophrenia”. In (ed.) G. Mallarkey: Managing Schizophrenia - Adis International; pgs. 59-75, 1999.
- **Awad A.G.**: “Behavioural and Subjective Effects of Atipsychotic Medications”. In J. Kane (ed); Managing the Side-Effects of Drug Therapy in Schizophrenia. SP Science Press 2001, pp 1 -14.
- **Awad A.G.**, “Antipsychotic Medications - How Satisfied Are Our Patients”. In: Patient Satisfaction, Compliance and Outcomes in Schizophrenia. (Eds.) Hellewell J., Awad A.G., Clear Perspectives Series; Shire Hall Publications, London, U.K, 1999.
- **Awad A.G.**, Voruganti L.N.P, “Neuroleptics and Quality of Life in Schizophrenia” In: Quality of Life and Mental Health Care. (Eds.) Priebe S., Oliver J., Kaiser W. Wrightson Biomedical Publishing, London U.K. Pgs 119-125, 1999.
- Lozon J., Rowand S., **Awad A.G.**, de Waal L., Moffat M., “Strategic Alliances in Health Care.” The Wellesley/St. Michael’s Mental Health Program in: Strategic Alliances in Health Care. Eds: P. Leatt et al, Canadian College of Health Services Executives 1996, pps. 31-40.
- **Awad A.G.**, “Psychopharmacology Research in Canada.” In Images in Psychiatry: Ed: Rae-Grant Q. World Psychiatric Association Publication - American Psychiatric Press, Washington.
- **Awad A.G.**, “Quality of Life Issues in Medicated Schizophrenics.” In Contemporary Issue in the Treatment of Schizophrenia. Eds. C.L. Shriqui and H. Nasrallah. American Psychiatric Press, 1995.

- **Awad A.G.**, “Prediction of Response to Neuroleptic Therapy - State of the Art 1978-1993.” In Prediction of Outcome to Neuroleptic Therapy in Schizophrenia - Conceptual and Methodological Issues. Springer, Vienna 1994.
- **Awad A.G.**, Gaebel W., “Prediction Research in Neuroleptic Therapy - Future Directions.” In Prediction of Outcome to Neuroleptic Therapy in Schizophrenia - Conceptual and /Methodological Issues. Springer, Vienna, 1994.
- **Awad A.G.**, The Use of Psychotropic Drugs in the Elderly. In Disturbed Behaviour in the Elderly, eds. A.G. Awad, H.B. Durost, W.O. McCormick, H.M.R. Meier. Toronto, Pergamon Press, 1987.
- **Awad A.G.**, “Peer Review and the Use of Psychotropic Drugs in Psychiatry.” In Evaluation of Quality of Care and Peer Review in Psychiatry. Eds. A.G. Awad, H.B. Durost, W.O. McCormick. Toronto, Pergamon Press, 1980.
- Sen A.K., Murphy R., Stancer H.C., **Awad A.G.**, Godse D.D., Grof P., “On the Mechanism of Action of Lithium in Affective Disorders - A New Hypothesis.” In Membrane and Diseases. Eds. J. Hoffman, L. Bolis, A. Leaf. New York, Raven Press, 1976.

• Books

- “Quality of Life Impairment in Schizophrenia, Mood Disorders and Anxiety: New Perspective on Treatment and Research”. (Eds.) Ritsner, Michael (Haifa, Israel), **Awad, A.G.** (Toronto, Canada); Springer 2007
- “Patient Satisfaction, Compliance and Outcomes in Schizophrenia”. (Eds.) Hellewell J., **Awad A.G.**, Clear Perspectives Series; Shire Hall Publications, London, U.K. 1999.
- “Prediction of Outcome to Neuroleptic Therapy in Schizophrenia - Conceptual and Methodological Issues.” (Eds.) Gaebel W., **Awad A.G.**, Springer Verlag, Vienna, 1994.
- “Disturbed Behaviour in the Elderly.” (Eds.), **A.G. Awad**, Durost H.B., McCormick W.O., Meir H.M.R., Toronto, Pergamon Press, 1987.
- “Evaluation of Quality of Care in Psychiatry.” (Eds.), **A.G. Awad**, H.B. Durost, W.O. McCormick. Toronto, Pergamon Press, 1980.

Commissioned Reports

- Review of the Graduate Studies Program, Department of Psychiatry, University of Alberta, Edmonton 2003.
- Review of Department of Psychiatry & Mental Health Program, Lambton Hospitals Group, Sarnia, Ontario, September 2001.
- Review of Nova Scotia Psychiatric Hospital, Halifax, Nova Scotia, October 1997.
- Review of Whitby Psychiatric Hospital, Whitby, Ontario, March 1997.
- Review of Child and Parent Resource Centre, London, Ontario, March 1997.
- Review of Clinical Programs, Alberta Psychiatric Hospital, Edmonton, Alberta, November 1996.
- Review of the Regional Forensic Psychiatric Centre, Saskatoon, Saskatchewan, May 1996.
- Review of the Department of Psychiatry, St. Joseph’s Health Centre, London, Ontario, June 1994.
- Review of Psychiatric Services, St. Boniface Hospital, Winnipeg. Report Submitted to Ministry of Health, Manitoba, 1993.
- Review of Psychiatric Services, Grace Hospital, Winnipeg, Manitoba. Report Submitted to Ministry of Health, Manitoba, 1992.
- Review of Emergency Psychiatric Services. Department of Psychiatry, Mount Sinai Hospital, Toronto, 1991.

- Review of Psychiatric Services and Medical Staff Organization, Brockville Psychiatric Hospital. Report Commissioned by the Ontario Ministry of Health, 1990.
- Review of Psychiatric and Mental Health Programs. Peel Memorial Hospital, 1989. Commissioned by the Board of Directors.
- Review of Psychiatric Program, Medical Staff Services and Organization, London Psychiatric Hospital. Medicus of Canada, Commissioned By the Ministry of Health of Ontario, 1988.

George Awad

August 27, 2015